These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 30386806)

  • 1. Evaluation of markers of outcome in real-world treatment of diabetic macular edema.
    Campos A; Campos EJ; do Carmo A; Caramelo F; Martins J; Sousa JP; Ambrósio AF; Silva R
    Eye Vis (Lond); 2018; 5():27. PubMed ID: 30386806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Choroidal thickness changes stratified by outcome in real-world treatment of diabetic macular edema.
    Campos A; Campos EJ; do Carmo A; Patrício M; Castro de Sousa JP; Ambrósio AF; Silva R
    Graefes Arch Clin Exp Ophthalmol; 2018 Oct; 256(10):1857-1865. PubMed ID: 30039271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Temporal variation of optical coherence tomography biomarkers as predictors of anti-VEGF treatment outcomes in diabetic macular edema.
    Maggio E; Mete M; Sartore M; Bauci F; Guerriero M; Polito A; Pertile G
    Graefes Arch Clin Exp Ophthalmol; 2022 Mar; 260(3):807-815. PubMed ID: 34661731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anatomical and functional responses in eyes with diabetic macular edema treated with "1 + PRN" ranibizumab: one-year outcomes in population of mainland China.
    Lai K; Huang C; Li L; Gong Y; Xu F; Zhong X; Lu L; Jin C
    BMC Ophthalmol; 2020 Jun; 20(1):229. PubMed ID: 32539744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spectral-Domain OCT Predictors of Visual Outcomes after Ranibizumab Treatment for Macular Edema Resulting from Retinal Vein Occlusion.
    Yiu G; Welch RJ; Wang Y; Wang Z; Wang PW; Haskova Z
    Ophthalmol Retina; 2020 Jan; 4(1):67-76. PubMed ID: 31669329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment response to Conbercept of different types of diabetic macular edema classified based on optical coherence tomography].
    Zhang Y; Yao J; Quan Y; Wang J; Xing Y; Zhou A
    Nan Fang Yi Ke Da Xue Xue Bao; 2021 Oct; 41(10):1501-1508. PubMed ID: 34755665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diabetic Macular Edema With and Without Subfoveal Neuroretinal Detachment: Two Different Morphologic and Functional Entities.
    Vujosevic S; Torresin T; Berton M; Bini S; Convento E; Midena E
    Am J Ophthalmol; 2017 Sep; 181():149-155. PubMed ID: 28687219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Baseline Subfoveal Choroidal Thickness as a Predictor for Response to Short-Term Intravitreal Bevacizumab Injections in Diabetic Macular Edema.
    Dweikat A; Jarrar A; Akkawi M; Shehadeh M; Aghbar A; Qaddumi J; Akkawi M
    Clin Ophthalmol; 2021; 15():4175-4180. PubMed ID: 34703204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imaging retinal inflammatory biomarkers after intravitreal steroid and anti-VEGF treatment in diabetic macular oedema.
    Vujosevic S; Torresin T; Bini S; Convento E; Pilotto E; Parrozzani R; Midena E
    Acta Ophthalmol; 2017 Aug; 95(5):464-471. PubMed ID: 27775223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Visual Acuity in Retinal Vein Occlusion, Diabetic, and Uveitic Macular Edema: Central Subfield Thickness and Ellipsoid Zone Analysis.
    Ciulla TA; Kapik B; Grewal DS; Ip MS
    Ophthalmol Retina; 2021 Jul; 5(7):633-647. PubMed ID: 33130256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of Visual Acuity Outcomes after Anti-Vascular Endothelial Growth Factor Treatment for Macular Edema Secondary to Central Retinal Vein Occlusion.
    Sen P; Gurudas S; Ramu J; Patrao N; Chandra S; Rasheed R; Nicholson L; Peto T; Sivaprasad S; Hykin P
    Ophthalmol Retina; 2021 Nov; 5(11):1115-1124. PubMed ID: 33610836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baseline choroidal thickness as a predictor for response to anti-vascular endothelial growth factor therapy in diabetic macular edema.
    Rayess N; Rahimy E; Ying GS; Bagheri N; Ho AC; Regillo CD; Vander JF; Hsu J
    Am J Ophthalmol; 2015 Jan; 159(1):85-91.e1-3. PubMed ID: 25261844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Ranibizumab and aflibercept for diabetic macular edema-retrospective study with real-life data after 12 months].
    Holbach B; Zeman F; Helbig H; Gamulescu MA
    Ophthalmologe; 2020 Jul; 117(7):687-692. PubMed ID: 31705192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Real-World Study of Dexamethasone Implant in Treatment-Naïve Patients with Diabetic Macular Edema: Efficacy and Correlation Between Inflammatory Biomarkers and Treatment Outcome.
    Vadalà M; Sunseri Trapani V; Guarrasi G; Ventura N; Castellucci M; Cillino S
    Clin Ophthalmol; 2020; 14():2657-2665. PubMed ID: 32982158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dexamethasone for unresponsive diabetic macular oedema: optical coherence tomography biomarkers.
    Bonfiglio V; Reibaldi M; Pizzo A; Russo A; Macchi I; Faro G; Avitabile T; Longo A
    Acta Ophthalmol; 2019 Jun; 97(4):e540-e544. PubMed ID: 30318792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diabetic macular edema with neuroretinal detachment: OCT and OCT-angiography biomarkers of treatment response to anti-VEGF and steroids.
    Vujosevic S; Toma C; Villani E; Muraca A; Torti E; Florimbi G; Leporati F; Brambilla M; Nucci P; De Cilla' S
    Acta Diabetol; 2020 Mar; 57(3):287-296. PubMed ID: 31541333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ranibizumab versus aflibercept for diabetic macular edema: 18-month results of a comparative, prospective, randomized study and multivariate analysis of visual outcome predictors.
    Chatzirallis A; Theodossiadis P; Droutsas K; Koutsandrea C; Ladas I; Moschos MM
    Cutan Ocul Toxicol; 2020 Dec; 39(4):317-322. PubMed ID: 32722955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome and Predictors for 2-Year Visual Acuity in Eyes with Diabetic Macular Edema Treated with Ranibizumab.
    Eski Yucel O; Birinci H; Sullu Y
    J Ocul Pharmacol Ther; 2019 May; 35(4):229-234. PubMed ID: 30896316
    [No Abstract]   [Full Text] [Related]  

  • 19. Predictive factors of better outcomes by monotherapy of an antivascular endothelial growth factor drug, ranibizumab, for diabetic macular edema in clinical practice.
    Sato S; Shinoda H; Nagai N; Suzuki M; Uchida A; Kurihara T; Kamoshita M; Tomita Y; Iyama C; Minami S; Yuki K; Tsubota K; Ozawa Y
    Medicine (Baltimore); 2017 Apr; 96(16):e6459. PubMed ID: 28422835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of Functional and Anatomic Outcomes in Patients with Diabetic Macular Edema Treated with Ranibizumab.
    Sophie R; Lu N; Campochiaro PA
    Ophthalmology; 2015 Jul; 122(7):1395-401. PubMed ID: 25870079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.